title: Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
abstract: BACKGROUND
  Interim PET scans in HIV-negative patients with Hodgkin lymphoma has emerged as one of the most important prognostic tools. However, equivalent studies in HIV-positive patients are yet to be performed.
  
  
  OBJECTIVE
  We evaluated the prognostic value of interim [18F]-fluoro-2-deoxy-D-glucose-PET (18F-FDG PET) after two or three cycles of chemotherapy using adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) with concomitant HAART in HIV-positive patients with Hodgkin lymphoma.
  
  
  METHODS
  Patients with advanced HIV-Hodgkin lymphoma (HIV-HL) from six UK centres were included. Interim PET scans after two or three cycles of ABVD (PET-2 or PET-3) were carried out. Prognostic analysis correlated the 2-year progression-free survival (PFS) rate with the interim PET result.
  
  
  RESULTS
  Twenty-three evaluable patients were assessed, 21 achieved a negative interim PET and 22 achieved complete remission by computerized tomography scan criteria after ABVD therapy. After a median follow-up of 27 months (range 12-50), disease progression was seen in one patient. Treatment failure was seen in one of the two interim PET-positive patients and none of the interim PET-negative patients. The 2-year PFS for interim PET-positive patients was 50%, and 100% for interim PET-negative patients (P = 0.0012).
  
  
  CONCLUSIONS
  A negative interim 18F-FDG PET result is highly predictive of treatment success in HIV-HL patients.
authors.affiliation: Department of Haematology, Royal Free Hampstead NHS Trust, London, UK.
authors.forename: Jessica
authors.initials: J
authors.lastname: Okosun
authors.forename: Victoria
authors.initials: V
authors.lastname: Warbey
authors.forename: Kate
authors.initials: K
authors.lastname: Shaw
authors.forename: Silvia
authors.initials: S
authors.lastname: Montoto
authors.forename: Paul
authors.initials: P
authors.lastname: Fields
authors.forename: Robert
authors.initials: R
authors.lastname: Marcus
authors.forename: Andres
authors.initials: A
authors.lastname: Virchis
authors.forename: Christopher
authors.initials: C
authors.lastname: McNamara
authors.forename: Mark
authors.initials: M
authors.lastname: Bower
authors.forename: Kate
authors.initials: K
authors.lastname: Cwynarski
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D001761:Bleomycin / Q000627:therapeutic use; D003606:Dacarbazine / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy; D006689:Hodgkin Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000000981:diagnostic imaging* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014747:Vinblastine / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin